Gefarnate - Docslib

Sign Up
Log In
Upload

Sign Up
Log In
Upload

Home
» Tags
» Gefarnate

Gefarnate

Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Jp Xvii the Japanese Pharmacopoeia
Evidence-Based Clinical Practice Guidelines for Peptic Ulcer Disease 2015
Prevalence of Anti-Ulcer Drug Use in a Chinese Cohort
Supplement Ii to the Japanese Pharmacopoeia Seventeenth Edition
The Prevalence of Endoscopic Gastric Mucosal Damage in Patients with Rheumatoid Arthritis
Morphological Study of Gastric Lesions Developing in the Rat Under Several Damaging Conditions: Modifications Induced by Pretreatment with Zinc Acexamate
United States Patent (19) 11) Patent Number: 5,457,128 Yanagawa 45 Date of Patent: Oct
(12) Patent Application Publication (10) Pub. No.: US 2015/0050713 A1 Malakhov Et Al
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Drug Class Review Proton Pump Inhibitors
Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Review Article Consensus on Chronic Gastritis in China (9-10 November 2012 Shanghai)
Changes Highlighted Final Version Date of Issue
Pharmaabkommen A1 E
Nasally Administrable Compositions Containing Physiologically Active Peptides

Top View

(12) United States Patent (10) Patent No.: US 8,414.914 B2 Bromley Et Al
Section B Changed Classes/Guidelines Final
Australian Statistics on Medicines 2009
Sustained Release Preparation
(12) Patent Application Publication (10) Pub. No.: US 2005/0089577 A1 Yokoyama Et Al
United States Patent (19) 11) Patent Number: 5,620,964 Roth Et Al
Therapeutic Class Overview Proton Pump Inhibitors
Oregon Drug Use Review / Pharmacy & Therapeutics Committee
Lopresti, Michael1 1Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan
Harmonized Tariff Schedule of the United States (2006) (Rev
Lansoprazole for Secondary Prevention of Gastric Or Duodenal Ulcers Associated with Long-Term Non-Steroidal Anti-Inflammatory Dr
Therapeutic Class Overview Proton Pump Inhibitors Single Entity Agents
Adherence to the Preventive Strategies for Nonsteroidal Anti-Inflammatory Drug
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Klasifikacija ATC 2021
Difference in Mode of Action of Cimetidine Ane Gefarnate on Endogenous Prostacyclin, Prostaglandin E2 and Thromboxane in Rat Gastric Mucosa
(12) United States Patent (10) Patent No.: US 7,026,360 B1 Fest0 (45) Date of Patent: Apr
Endogenous Prostaglandin E Human and Experimental Duodenal

© 2024 Docslib.org Feedback